HCM: Rounding Bottom detected on 22 Oct 2026

HCM is forming a rounding bottom pattern with moderately strong structure and volume confirmation. The stock trades at $14.37, caught between key support at $9.77 and resistance at $14.78—currently positioned 47% above its 52-week low and 12% below the 52-week high. The pattern quality score of 71 (structure: 13/15, breakout: 12/13, volume: 12/12) reflects solid confirmation: volume ratio of 1.36x average and RSI of 55.77 indicate accumulation without overbought conditions. A prior bull flag detected on July 30 with 28.9 quality score provides historical pattern context. The setup suggests early-stage reversal development with 67.65% win probability.

HUTCHMED closed its exclusive development and license agreement with GSK for HMPL-A830 on October 21, 2026, triggering an expected $110 million upfront payment and up to $1.185 billion in contingent milestone payments. This recent deal completion marks the most immediate catalyst. H1 2026 showed oncology sales surged over 40% in China and 70% ex-U.S., with strong cash reserves maintained. On September 28, 2026, HUTCHMED announced submission of US NDA for ORPATHYS® plus TAGRISSO® in MET-driven EGFR-mutated lung cancer. As of June 30, 2026, HUTCHMED held $1,374.8 million in cash and had net income of $15.9 million. The biotechnology sector displays a bullish regime (0.91 score), while the broader market is neutral. These catalysts—GSK deal closure, strong oncology growth, and multiple late-stage trials—are driving the pattern formation.

A successful rounding bottom breakout would see HCM decisively close above resistance at $14.78, targeting a conservative price of $15.21 based on measured move calculation—approximately 5.8% upside from current levels. Volume confirmation would require sustained volume above the 1.36x ratio already present. Historical win probability of 67.65% suggests roughly 2:1 favorable odds on the setup. The pattern invalidates if price closes below the key support level of $9.77, a 32% drawdown that would signal failed accumulation and resumption of downtrend. The low beta of 0.29 and moderate ATR% of 3.41 indicate this stock will move with lower volatility than broad market, requiring patience for the measured move.

MACD histogram is negative at -0.0129, showing momentum slightly lagging price—a warning sign that breakout confirmation may be fragile if volume deteriorates. No imminent earnings date is flagged, but quarterly results timing should be monitored. The stock's 31% gain over three months has created some extended positioning; RSI at 55.77 provides cushion before overbought territory (>70), but mean-reversion risk exists if the GSK deal benefits are already priced in. Geopolitical risks specific to China biotech remain a structural concern (regulatory scrutiny, capital controls). The bull flag pattern from July 30 failed to produce sustained momentum (28.9 quality), suggesting prior breakout attempts have faltered—investors should verify volume sustains at breakout.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.